DexCom's key Q3 earnings factors include Stelo sales, updates on sales channels, and potential share buybacks. See why I ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A robust ...

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A ...

DexCom's newest G7 CGM competes closely with Abbott's FreeStyle Libre 3, both products have very similar features and design innovations. DexCom's forward multiples suggest the company is trading ...

But even if we aren't in a bear market, buying shares of beaten-down stocks that have what it takes to recover is also an ...

A top healthcare stock to own over the years has been DexCom (NASDAQ: DXCM). The company makes continuous glucose monitors ...

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an ...

Today, DexCom is the leading CGM company, with an estimated 40% market share. Importantly, CGM products are relatively nascent. DexCom generates nearly $4 billion in annual sales on a user base of ...

The International Longshoremen’s Association strike is a test of whether unions can push back against a wave of automation ...

At its current valuation, DexCom stock is the opposite of a bargain. Even after its big drop over the summer, it would still be a risky stock to buy now. Those who are interested would probably do ...

Jessica is a writer on the Wellness team with a focus on health technology, eye care, nutrition and finding new approaches to chronic health problems. When she's not reporting on health facts, she ...

Strong Product Demand: We are upbeat about DexCom's continued strength in its CGM products. The company continues to expand its product portfolio with the addition of new products like G7 in 2023 ...